Bionano Genomics: HC Wainwright Raises PT to $11 from $10, Maintains Buy

Bionano Genomics: HC Wainwright Raises PT to $11 from $10, Maintains Buy

Title: Bionano Genomics: HC Wainwright Raises PT to $11 from $10, Maintains Buy

Bionano Genomics Inc. (NASDAQ: BNGO), a life sciences instrumentation company specializing in genome analysis, has seen a significant update in its analyst coverage. HC Wainwright & Co. has raised its price target for Bionano Genomics from $10 to $11, while maintaining a "Buy" rating. This move comes as the company is set to release its latest quarterly earnings report on Thursday, August 14, 2025.

The update from HC Wainwright reflects optimism about the company's potential for growth and profitability. Bionano Genomics has been facing challenges, including a decline in revenue and negative earnings growth. However, the analyst's revised price target indicates a belief in the company's ability to turn around its financial performance.

Analysts' Optimism

HC Wainwright's analyst team expects Bionano Genomics to report an earnings per share (EPS) of $-2.87 for the quarter ending August 14, 2025. While this is not a positive EPS figure, it is a notable improvement over the previous quarter's EPS of $-3.49. The company's shares have been trading at $3.08 as of August 12, reflecting a 89.47% decline over the last 52 weeks.

Earnings History

Looking at the company's past performance, Bionano Genomics has shown mixed results. In the last quarter, the company reported an EPS beat by $2.34, leading to a 5.08% increase in the share price on the subsequent day. However, over the past year, the company has experienced significant declines in its EPS and revenue growth, which has negatively impacted its stock price.

Peer Comparison

In comparison to its peers, Bionano Genomics ranks at the bottom in terms of revenue growth, gross profit, and return on equity. This indicates that the company is lagging behind its competitors in key financial metrics. Despite this, the analyst's revised price target suggests that there is potential for improvement and growth.

Future Outlook

The company's revenue is forecast to grow at an average rate of 24% per annum over the next three years, which is significantly higher than the 6.0% growth forecast for the Life Sciences industry in the US. This growth projection is a positive sign for investors, as it indicates that the company has the potential to turn around its financial performance.

Conclusion

The update from HC Wainwright highlights the analyst's optimism about Bionano Genomics' future prospects. While the company has faced significant challenges in the past, the revised price target and growth projections indicate a belief in the company's ability to improve its financial performance. Investors should closely monitor the company's earnings report on August 14, 2025, to gauge the extent of this optimism.

References

[1] https://www.benzinga.com/insights/earnings/25/08/47101593/a-preview-of-bionano-genomics-earnings
[2] https://finance.yahoo.com/news/bionano-genomics-second-quarter-2025-142219941.html